SALT LAKE CITY, Oct. 18, 2021 /PRNewswire/
-- DiscGenics, Inc., a clinical stage biopharmaceutical
company focused on developing regenerative cell-based therapies
that alleviate pain and restore function in patients with
degenerative diseases of the spine, today announced that Goldman
Sachs (NYSE:GS) recognized DiscGenics Chairman and CEO Flagg Flanagan as one of the 100 Most Intriguing
Entrepreneurs of 2021 at its Builders + Innovators Summit in
Healdsburg, California.
Goldman Sachs selected Mr. Flanagan as one of 100 entrepreneurs
from multiple industries to be honored at the two-day event.
Mr. Flanagan has over 30 years of experience in the medical
device field as an entrepreneur, executive and advisor. He has led
DiscGenics since its founding in 2007 and has overseen its
evolution from pre-clinical to clinical phase with its first
product candidate, IDCT (rebonuputemcel), an injectable disc cell
therapy, now in clinical trials in the U.S. and Japan for degenerative disc disease (DDD).
"I am honored to receive this recognition from Goldman Sachs and to
be among such an innovative group of entrepreneurs," said Mr.
Flanagan. "I am extremely proud of our team at DiscGenics and
remain incredibly excited about the opportunity before us to
potentially help millions of patients with debilitating back
pain."
Prior to DiscGenics, Mr. Flanagan founded Flanagan Instruments,
which he built over 24 years into a leading neurosurgical device
distribution business before selling it to Itochu International in
2005. Mr. Flanagan is currently on the boards of TrueDigital
Systems, Peleton Medical, Triad Life Sciences, Steribite, and the
Neurosurgery Research & Education Foundation. He has also
served on the boards of the Alliance for Regenerative Medicine, as
well as TrueVision Systems and Image Stream Medical, which were
acquired by Alcon and Olympus, respectively.
"Innovation doesn't happen just anywhere; it thrives where
there's a wide range of thoughts and perspectives," said
David M. Solomon, Chairman & CEO
of Goldman Sachs. "One of our great strengths is our ability to
bring together people from different walks of life and to spark
conversations today that will lead to breakthroughs tomorrow. The
leaders we've chosen to highlight at our Builders + Innovators
Summit are truly remarkable, and we are pleased to recognize
Flagg Flanagan as one of this year's
most intriguing entrepreneurs."
In addition to honoring 100 entrepreneurs, the summit consists
of general sessions and clinics led by seasoned entrepreneurs,
academics and business leaders as well as resident scholars.
About DiscGenics
DiscGenics is a privately held,
clinical stage biopharmaceutical company focused on developing
regenerative cell-based therapies that alleviate pain and restore
function in patients with degenerative diseases of the spine. As
the only company in the world to develop an allogeneic cell therapy
derived from intervertebral disc cells to treat diseases of the
disc, DiscGenics believes it has a unique opportunity to harness
the restorative potential of the human body to heal millions of
patients suffering from the debilitating effects of back pain.
DiscGenics' first product candidate, IDCT, is a homologous,
allogeneic, injectable cell therapy that utilizes biomedically
engineered progenitor cells derived from intervertebral disc
tissue, known as Discogenic Cells, to offer a non-surgical,
potentially regenerative solution for the treatment of patients
with mild to moderate degenerative disc disease. For more
information, visit discgenics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/discgenics-honored-by-goldman-sachs-for-entrepreneurship-301401570.html
SOURCE DiscGenics, Inc.